In 2024, a panel of leading scientists made a proposal that would have seemed absurd just a decade earlier: they asked the FDA to formally recognise aging itself as a medical condition that can be treated with a drug. The compound they proposed to study was not a newly engineered molecule from a biotech lab — it was metformin, a drug derived from French lilac, discovered in 1922 and used to treat type 2 diabetes for more than 60 years. The trial they designed — the TAME trial — represents the most serious scientific attempt yet to slow human biological aging. And the evidence behind it is more striking than most people realise.
Key Takeaways
- Metformin is one of the safest, most widely prescribed drugs in the world — in clinical use for over 60 years with an outstanding safety record
- A landmark UK study found diabetics on metformin lived longer than matched healthy non-diabetics not on any drug — suggesting a genuine anti-aging effect beyond glucose control
- Metformin activates AMPK and suppresses mTOR — the same cellular pathways activated by fasting and caloric restriction
- The TAME trial (Targeting Aging with Metformin) is the first FDA-approved clinical trial to formally target biological aging as a treatable condition — results expected 2028–2030
- Important caveat: metformin may blunt exercise-induced mitochondrial adaptation — a significant consideration for physically active people
What Is Metformin — and Why Are Longevity Scientists Excited About It?
Metformin is a biguanide compound originally derived from Galega officinalis — the French lilac plant — which has been used in European folk medicine for centuries to treat what was historically described as “frequent urination” (likely diabetes). It was first synthesised in 1922, approved for diabetes treatment in the UK in 1958, and became one of the most widely prescribed drugs in the world after FDA approval in 1995. Approximately 150 million people take it today, making it one of the most studied drugs in medical history.
For most of that history, metformin was understood narrowly: it lowers blood glucose by reducing the liver’s glucose output and improving insulin sensitivity in peripheral tissues. But a series of unexpected findings in the 2000s and 2010s completely changed its profile. Researchers noticed that diabetics on metformin were not just controlling their blood sugar — they were getting cancer less often, experiencing less cardiovascular disease, showing slower cognitive decline, and living longer than comparable diabetics on other drugs. More remarkably, some studies found they were outliving healthy non-diabetics not on any medication at all.
This triggered intensive research into what metformin was actually doing at the cellular level — and the answer pointed directly to the fundamental biology of aging.
How Metformin Targets the Biology of Aging
Metformin’s anti-aging mechanisms operate through two interconnected pathways that sit at the heart of longevity science:
The Two Core Mechanisms of Metformin’s Anti-Aging Effect
AMPK Activation. Metformin activates AMPK (AMP-activated protein kinase) — the cell’s master energy sensor. When AMPK is active, the cell enters a conservation and repair mode: it promotes autophagy (cellular cleanup), improves mitochondrial efficiency, reduces inflammatory signalling, and suppresses unnecessary protein synthesis. This is the same pathway activated by caloric restriction and intermittent fasting — which is why metformin is sometimes called a “caloric restriction mimetic.” You get some of the same molecular benefits of fasting without actually fasting.
mTOR Suppression. By activating AMPK, metformin indirectly reduces mTOR (mechanistic target of rapamycin) activity. mTOR is the cell’s growth accelerator — it drives protein synthesis, cell division, and growth when nutrients are abundant. Chronically elevated mTOR activity is one of the most consistent features of accelerated biological aging. Suppressing mTOR — as fasting, rapamycin, and now metformin do — extends healthy lifespan in virtually every organism ever studied, from yeast to mice to primates.
Beyond these two primary mechanisms, metformin also reduces systemic inflammation (measurable reductions in CRP and IL-6), improves gut microbiome composition favourably, and appears to reduce the rate of DNA damage accumulation that drives cellular aging. It is, in the language of longevity research, a remarkably “pleiotropic” drug — it hits multiple aging hallmarks simultaneously.
The Evidence That Made Scientists Take Notice
The most cited piece of evidence for metformin’s anti-aging effect comes from a 2014 Cardiff University study published in Diabetes, Obesity and Metabolism. Researchers compared 78,000 diabetics on metformin, 12,000 diabetics on sulphonylurea drugs, and a large matched cohort of healthy non-diabetics.
The finding was arresting: people with type 2 diabetes taking metformin lived slightly longer than matched healthy controls who were not taking any diabetes medication. A population with a serious metabolic disease was outliving a healthier comparison group. The only credible explanation was that metformin was producing a biological benefit beyond glucose management.
Additional lines of evidence:
- A 2019 meta-analysis of 53 studies found metformin use associated with a 31% reduction in all-cause cancer incidence in diabetic populations — an effect far too large to be explained by glucose control alone
- Metformin users show measurably lower biological age scores on epigenetic clock measures compared to comparable non-users, in multiple independent datasets
- Animal studies in mice, C. elegans, and Drosophila consistently show lifespan extension with metformin treatment
- A 2020 study found metformin use in older adults associated with significantly slower progression of age-related functional decline over a 10-year follow-up
The TAME Trial: Formally Targeting Aging for the First Time
In 2020, the FDA took an unprecedented step: it granted Investigational New Drug approval for the TAME trial (Targeting Aging with Metformin), accepting the premise that biological aging is a modifiable process that can be the primary target of a clinical intervention. This was the first time a regulatory body had formally treated aging itself — not a specific disease — as the target of a drug trial.
TAME is enrolling 3,000 adults aged 65–79 across 14 sites in the United States. Half receive metformin 1,500mg daily; half receive placebo. The primary endpoint is not any single disease — it is the composite rate of developing any age-related condition from a cluster of five: cardiovascular disease, cancer, dementia, physical disability, and death. The trial is explicitly testing whether metformin can compress the window of morbidity — delaying the onset of these conditions as a whole, effectively extending healthy lifespan.
Results are expected between 2028 and 2030. If positive, it will be the most consequential medical finding in decades.
The Exercise Controversy: A Critical Limitation
Metformin’s most important limitation for healthy non-diabetic people is its potential interference with exercise adaptation — the biological process by which exercise makes you fitter and longer-lived. A 2019 study published in Aging Cell found that healthy older adults taking metformin during an exercise training programme showed significantly blunted improvements in aerobic capacity and insulin sensitivity compared to peers doing the same exercise on placebo.
The mechanism is specific: metformin appears to suppress mitochondrial biogenesis — the creation of new mitochondria that is the central molecular benefit of aerobic exercise for longevity. In other words, metformin and exercise may partially cancel each other out in the very pathway — mitochondrial health — where exercise does some of its most important anti-aging work. For sedentary people, this trade-off may not matter. For people who exercise regularly, it is a serious consideration.
For those interested in the AMPK activation and mTOR suppression pathways that make metformin compelling — without the prescription requirement or the exercise interference issue — berberine is the most evidence-backed natural compound working through overlapping mechanisms. Check out this highly-rated berberine supplement on Amazon.in — widely used in India as a metabolic health and longevity support compound.
Watch: Protecting Your Brain from Aging
The longevity pathways activated by metformin — AMPK, mTOR, autophagy — are the same ones that protect against dementia. Watch our full video explanation: Dementia Is Not Inevitable — 8 Science-Backed Ways to Protect Your Brain
Dr. Ajit Jha’s Clinical Perspective
“Metformin is a drug I know extremely well — I have been prescribing it for type 2 diabetes for over two decades. It is one of the safest drugs in medicine, and the longevity research is genuinely compelling. My current position is this: if a patient is a type 2 diabetic or pre-diabetic, metformin is almost always the first medication I reach for — and the longevity data makes that choice even more confident than before. For healthy non-diabetics asking about it specifically for anti-aging, I am cautious. The exercise interference data is real and matters. I would not recommend metformin off-label to someone who exercises regularly and has good metabolic health — they are likely getting more longevity benefit from their training programme than metformin would add, and the two may partially work against each other. Wait for the TAME results. In the meantime: exercise consistently, eat real food, manage your sleep, and if you have any metabolic risk factors, get a fasting glucose and HbA1c checked. Those interventions have stronger evidence right now than off-label metformin for anti-aging in healthy people.”
— Dr. Ajit Jha, MD Medicine | IMA Lifetime Member | Editorial Board Member, International Journal of Diabetes and Endocrinology (IJDE)
Frequently Asked Questions
Can healthy people take metformin for anti-aging?
Not with robust evidence yet. Metformin is a prescription drug, and off-label use for anti-aging in non-diabetics remains experimental. The TAME trial is specifically designed to answer this question in healthy older adults. Until those results are published (expected 2028–2030), using metformin for anti-aging outside a diagnosed metabolic condition and medical supervision is not supported by current clinical guidelines. Some longevity physicians in the US and Europe prescribe it off-label at low doses, but this is not standard of care.
What dose is the TAME trial using?
The TAME trial uses 1,500mg per day (750mg twice daily with meals), which is in the lower-to-middle range of doses used for type 2 diabetes treatment (which can go up to 2,550mg daily). Lower doses appear sufficient for the AMPK activation effects while minimising the gastrointestinal side effects — nausea, diarrhoea, and stomach cramps — that are the most common reason people discontinue metformin.
Does metformin cause vitamin B12 deficiency?
Yes — this is a real and clinically important side effect that is often underappreciated. Long-term metformin use reduces B12 absorption in the gut in approximately 30% of users. B12 deficiency causes neurological symptoms including tingling, numbness, fatigue, memory problems, and, in severe cases, irreversible nerve damage. Anyone taking metformin long-term should have B12 levels checked annually and supplement aggressively if levels are falling — this is not optional monitoring.
How does metformin compare to berberine for anti-aging?
Both activate AMPK through related mechanisms. Metformin has 60+ years of human safety data, consistent evidence for cancer prevention, and a major ongoing trial. Berberine has significant clinical evidence for metabolic benefits comparable to metformin in short-term trials, plus additional mechanisms including gut microbiome modulation, and is available without a prescription. For healthy non-diabetics interested in AMPK pathway activation, berberine is the more accessible and arguably safer starting point until the TAME data is available.
📖 Related Articles